Dual-ligand functionalized liposomes with iRGD/trastuzumab co-loaded with gefitinib and lycorine for enhanced metastatic breast cancer therapy
Journal of Liposome Research,
Год журнала:
2025,
Номер
unknown, С. 1 - 15
Опубликована: Фев. 2, 2025
Personalized
treatment
strategies
have
greatly
improved
the
efficacy
of
anticancer
drugs.
Nanocarriers,
especially
liposomes,
function
as
excellent
platform
for
delivery
both
hydrophilic
and
hydrophobic
agents.
iRGD
is
a
peptide
composed
9-amino
acid
denoted
(iRGDP),
enhances
selective
intratumoral
Trastuzumab
(TMAB),
mainly
targets
HER2-positive
advanced
stage
breast
cancer
an
FDA-approved
monoclonal
antibody.
Gefitinib
(GEB)
drug,
effective
against
metastatic
(MBC),
while
Lycorine
hydrochloride
(LCOH),
naturally
derived
compound,
possess
anti-inflammatory
properties.
This
research
emphasizing
on
preparation
GEB
LCOH-entrapped
TPGS-COOH
coated-liposomes,
camouflaged
with
antibody
(TMAB)
cyclic
(iRGDP)
targeted
in
MBC
therapy.
The
developed
multifunctional
liposomes
were
studied
extensive
vitro
cell
line
studies
MCF-7
cells.
half-maximum
inhibitory
concentration
(IC-50)
values
LCOH
co-loaded
single
functionalized
liposome
(SFL)
(iRGDP-LiP,
TMAB-LiP)
dual-functionalized
(DFL)
(iRGDP-TMAB-LiP)
cells
1.04
±
0.023
μg/mL,
0.71
0.018
0.56
0.028
respectively.
Inverted
confocal
laser
scanning
microscopy
(ICLSM)
revealed
enhanced
cellular
internalization
SFL
DFL-treated
groups
tagged
coumarin-6
rhodamine-B
dye
compared
to
conventional
liposome.
scratch
assay
marked
reduction
migration,
DAPI
staining
confirmed
nuclear
condensation
(NC)
fragmentation
(NF)
groups.
Moreover,
flow
cytometry
demonstrated
early
late
apoptosis
DFL
These
findings
indicate
that
holds
promise
multifaceted
therapeutic
approach
Язык: Английский
Recent Advances in Smart Polymeric Micelles for Targeted Drug Delivery
Razhan Salah Othman,
Sara Zarei,
Hasan Rezaei Haghighat
и другие.
Polymers for Advanced Technologies,
Год журнала:
2025,
Номер
36(4)
Опубликована: Апрель 1, 2025
ABSTRACT
Smart
polymeric
micelles
have
emerged
as
versatile
nanocarriers
in
targeted
drug
delivery,
driven
by
their
unique
ability
to
encapsulate
therapeutic
agents
and
deliver
them
with
precision
specific
sites.
This
review
delves
into
the
recent
advancements
design,
functionality,
biomedical
applications
of
these
nanostructures,
emphasizing
role
enhancing
efficacy
while
minimizing
systemic
toxicity.
The
begins
discussing
principles
behind
stimuli‐responsive
micelles,
exploring
mechanisms
triggered
pH,
redox
conditions,
temperature,
light
achieve
controlled
release.
It
highlights
advances
functionalization
strategies,
including
surface
modifications
targeting
ligands
stimuli‐sensitive
linkages,
which
enhance
specificity
adaptability
pathological
microenvironments.
Subsequent
sections
focus
on
cutting‐edge
applications,
particularly
cancer
therapy,
regenerative
medicine,
theranostics,
showcasing
potential
addressing
complex
clinical
challenges.
Emerging
technologies,
such
multi‐stimuli‐responsive
systems
hybrid
are
explored
for
overcome
limitations
loading,
stability,
release
profiles.
Despite
significant
progress,
current
technologies
still
face
challenges,
achieving
consistent
reproducible
loading
efficiencies,
maintaining
stability
physiological
environments,
controlling
precise
kinetics,
ensuring
scalable
cost‐effective
production
methods.
concludes
a
discussion
challenges
future
perspectives
field,
need
integrating
advanced
polymer
chemistry,
nanotechnology,
biomedicine
develop
next‐generation
smart
micelles.
By
providing
comprehensive
overview,
this
article
aims
underscore
transformative
advancing
medicine
interventions.
Язык: Английский
Nanotechnology-Based Drug Delivery Systems, 2nd Edition
Pharmaceutics,
Год журнала:
2025,
Номер
17(1), С. 110 - 110
Опубликована: Янв. 15, 2025
Nanotechnology
is
a
promising
and
rapidly
developing
area
in
the
21st
century,
which
affects
various
fields
of
science:
physics,
chemistry,
biology,
engineering,
microelectronics,
medicine
[...]
Язык: Английский
Proof of Concept for the Single-Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular Oncoprotein
Опубликована: Янв. 1, 2025
Язык: Английский
Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(7), С. 3143 - 3143
Опубликована: Март 28, 2025
It
is
estimated
that
between
80
and
90%
of
mortality
in
cancer
patients
directly
or
indirectly
related
to
drug
resistance.
Consequently,
overcoming
resistance
represents
a
significant
challenge
the
treatment
cancer.
Integrins
are
transmembrane
adhesion
molecules
facilitate
linkage
extracellular
matrix
(ECM)
cytoskeleton,
thereby
enabling
activation
various
cellular
signaling
pathways.
highly
expressed
cancers
contribute
progression
through
invasion
metastasis.
In
addition,
recent
studies
have
revealed
integrins
play
pivotal
role
development
This
review
will
first
provide
an
overview
integrin
function
classification.
then
discusses
advances
understanding
how
cancer,
with
focus
on
ECM,
transporters,
epithelial-to-mesenchymal
transition
(EMT),
stemness,
PD-L1,
glycosylation.
Finally,
potential
applications
as
targets
for
therapeutic
agents
against
drug-resistant
also
summarized.
Язык: Английский
Unlocking the power of imidazoquinolines: recent advances in anticancer and immunotherapeutic strategies
Future Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown, С. 1 - 17
Опубликована: Апрель 15, 2025
The
challenges
in
drug
discovery
aiming
to
mitigate
cancer
progression
are
the
thrust
area
of
scientific
research
for
several
decades.
Since
advent
heterocyclic
chemistry,
programs
have
made
significant
achievements
that
lead
development
numerous
drugs
with
broad
spectrum
potencies,
contributing
both
diagnostic
and
therapeutic
advancements.
Till
date,
efforts
discover
more
potent
efficient
candidates
underway
minimize
adverse
side
effects
existing
chemotherapeutics.
In
view
above,
small-molecule
agonists
can
interact
different
immune
modulators
like
toll
receptor-7
(TLR-7)
TLR-8
being
investigated
explored.
These
expected
display
profound
effect
on
anti-tumoral
activity
by
enhancing
production
proinflammatory
cytokines.
Recently,
imidazoquinoline
derivatives
proven
TLR
agonist
activities
emerged
as
promising
anticancer
therapeutics.
With
advancements
technology
evolution
new
scopes
discovery,
strategies
adopted,
particularly
help
nanotechnology,
immune-technology,
combination
etc.,
curb
various
types
cancers.
Herein,
novel
therapeutics
imidazoquinolines
reported
last
5
years,
their
structure-activity
relationship
along
important
synthetic
schemes
agonists,
discussed.
Язык: Английский
Sorafenib—Drug Delivery Strategies in Primary Liver Cancer
Journal of Functional Biomaterials,
Год журнала:
2025,
Номер
16(4), С. 148 - 148
Опубликована: Апрель 21, 2025
Current
primary
liver
cancer
therapies,
including
sorafenib
and
transarterial
chemoembolization,
face
significant
limitations
due
to
chemoresistance
caused
by
impaired
drug
uptake,
altered
metabolism,
other
genetic
modulations.
These
challenges
contribute
relapse
rates
of
50–80%
within
five
years.
The
need
for
improved
treatment
strategies
(adjuvant
therapy,
unsatisfactory
enhanced
permeability
retention
(EPR)
effect)
has
driven
research
into
advanced
delivery
systems,
targeted
nanoparticles,
biomaterials,
combinatory
approaches.
Therefore,
this
review
evaluates
recent
advancements
in
pharmacotherapy,
focusing
on
the
potential
systems
its
derivatives.
Approaches
such
as
leveraging
Kupffer
cells
tumor
migration
or
utilizing
smaller
NPs
inter-/intracellular
delivery,
address
EPR
limitations.
Biomaterials
therapies
targeting
have
demonstrated
effectiveness
increasing
tumor-specific
but
clinical
evidence
remains
limited.
Combination
emerged
an
interesting
solution
overcoming
broadening
therapeutic
functionality.
Biomimetic
employing
blood
exosomes,
provide
methods
tumors,
preventing
metastasis,
strengthening
immune
responses.
However,
differences
between
preclinical
models
human
physiology
remain
a
barrier
translating
these
findings
success.
Future
must
focus
development
adjuvant
therapy
refining
overcome
heterogeneity
low
accumulation.
Язык: Английский